Table 2.
Lifetime Cannabis Use Disorder Status and Past 30-day Use and Adherence and PTSD Severity
| No CUD (SCID) n = 162a M (SD) or % |
CUD (SCID) n = 37a M (SD) or % |
No CB Last 30 n = 163a M (SD) or % |
CB Last 30 Days n = 27a M (SD) or % |
|
|---|---|---|---|---|
| Early Drop Out | 28.4% | 48.6% | 27.0% | 55.6% |
| Adherence | ||||
| Sertraline (mean) | 2.19 (1.10) | 2.16 (1.20) | 2.18 (1.04) | 2.62 (1.53) |
| PE In vivo (mean) | 3.02 (1.10) | 2.42 (1.15) | 3.09 (1.05) | 2.20 (1.18) |
| PE Imaginal (mean) | 2.66 (1.05) | 2.08 (1.04) | 2.68 (1.01) | 2.04 (1.23) |
| PTSD Severity (PSS-I) | ||||
| Pre-treatment | 29.14 (6.48) | 31.00 (7.00) | 29.61 (6.57) | 28.22 (6.70) |
| Post-treatment | 10.14 (9.29) | 19.21 (12.99) | 10.92 (10.27) | 14.00 (10.91) |
| 6-month follow-up | 7.95 (8.82) | 13.24 (10.33) | 8.46 (9.11) | 10.18 (11.19) |
| Pre- to 6-month | 2.16 | 1.72 | 2.14 | 2.00 |
| ES (Cohen's d) |
Note. CUD = Cannabis Use Disorder; SCID = Structured Clinical Interview for DSM-IV Lifetime Diagnosis; CB = Cannabis Use yes/no; PSS-I = Posttraumatic Symptom Scale-Interview. Means are original data, not imputed values. Effect sizes for PTSD severity were calculated using pooled means and standard deviations.
a
Sample size varied for this predictor with one participant missing cannabis use diagnosis on the SCID at baseline and 10 participants missing self-reported cannabis use on the ASI-SR at baseline.